5McGuire WP,Rowinskt EK.Paclitaxel in cancer treatment.I ST.New York:Marcel Dekker,1995:124
6Akerley W,Paclitaxel in advanced non-small cell lung cancer:an alternative high-dose weely schedule[J].Chest,2000;117(4 Suppl 1):152
7Chang AY,Kim K,Glick J,et al.Phase Ⅱ study of taxol,merbarone and piroxantrone in stage Ⅲ non-small cell lung cancer[J].Natl Cancer Inst,1993;85:388.
8周际昌.实用肿瘤内科学[M].北京：人民卫生出版社,1998.331.
9Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med,2002,346(2) : 92-98.
10Bunn PA, Soriano AF. Chemotherapeutic options in lung cancer.Cancer,1998,33(8): 1740-1750.
9Gokhan Gorgisen,Derya Ozes,Suray Pehlivanoglu,Abdullah Erdogan,Levent Dertsiz,Gulay Ozbilim,Irem Hicran Ozbudak,Burhan Savas,Osman Nidai Ozes.Differential expression and activation of Epidermal Growth Factor Receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC)[J].Experimental Lung Research.2013(9)
10O Fiala,M Pesek,J Finek,et al.Second line treatment in advanced non-small cell lung cancer (NSCLC):Compari-son of efficacy of erlotinib and chemotherapy[J].Neoplas-ma,2013,60(2):129-134.
